End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives.

@article{Hoeper2004EndPA,
  title={End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives.},
  author={Marius M Hoeper and Ronald J. Oudiz and Andrew Peacock and Victor F. Tapson and Sheila. G. Haworth and Adaani E. Frost and Adam Torbicki},
  journal={Journal of the American College of Cardiology},
  year={2004},
  volume={43 12 Suppl S},
  pages={48S-55S}
}
To date, randomized controlled clinical trials performed in pulmonary arterial hypertension (PAH) have been relatively short-term studies involving mainly patients with advanced disease. The primary end points in these trials have addressed exercise capacity, usually by using the 6-min walk test. Although this approach is still warranted in future trials assessing new treatments, it is likely that the focus will shift toward trials of longer duration, involving patients with less advanced… CONTINUE READING
66 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

Similar Papers

Loading similar papers…